Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567071 | 0.86 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3MAPK10 | |
| SCHEMBL6615141 | 0.84 | ADORA2A (0.51) | ADORA2AADORA1ADORA2BADORA3MAPK10 | |
| SCHEMBL5713438 | 0.76 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3MAPK10 | |
| SCHEMBL7146619 | 0.75 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5566888 | 0.75 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6017195 | 0.75 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3MAPK10 | |
| SCHEMBL2825553 | 0.74 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5038587 | 0.71 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL7154672 | 0.71 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5713547 | 0.71 | TP53 (0.41) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134854-A1 | Isonicotin- and nicotinamide derivatives of benzothiazoles | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134854-A1 | Isonicotin- and nicotinamide derivatives of benzothiazoles | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.